Vertex Pharmaceuticals (VRTX)
Health Care · Biotechnology · NASDAQ
Vertex is a leader in biotechnology primarily recognized for its dominance in cystic fibrosis therapy and its emerging pipeline of gene-editing treatments and non-opioid pain relief.
What Vertex Pharmaceuticals does
Vertex Pharmaceuticals is a global biotechnology company focused on developing and commercializing transformative medicines for serious diseases. The company is primarily known for its portfolio of cystic fibrosis (CF) treatments and has expanded into gene therapies for sickle cell disease and beta thalassemia, as well as development programs for acute and neuropathic pain.
Themes: cystic fibrosis, gene editing / gene therapy, pain management, rare diseases
Fundamentals
- Price$548.05 as of 2026-08-21 close
- Market cap$138.9B as of 2026-08-21
- 1-year return+37.9% 2025-08-21 close $397.46 → 2026-08-21 close $548.05
- P/E30.70 as of 2026-08-24
- Net margin+35.0% as of 2026-08-24
- Gross margin+86.0% as of 2026-08-24
- ROE+23.3% as of 2026-08-24
- Debt / equity0.00 as of 2026-08-24
- Revenue growth (YoY)+10.2% as of 2026-08-24
- Revenue CAGR (3y)+10.4% SEC XBRL
- Beta0.26 as of 2026-08-24
- Last reported earnings2026-08-03 SEC EDGAR Form 8-K (Item 2.02)
How VRTX compares in its sector
- price-to-earnings ratiomiddle range 203 covered Health Care peers, as of 2026-08-24
- net profit margintop 10% 504 covered Health Care peers, as of 2026-08-24
- operating margintop 10% 504 covered Health Care peers, as of 2026-08-24
- gross margintop 25% 384 covered Health Care peers, as of 2026-08-24
- return on equitytop 25% 576 covered Health Care peers, as of 2026-08-24
- 3-year revenue CAGRmiddle range 402 covered Health Care peers
- free cash flow (absolute dollars, latest fiscal year)top 10% 493 covered Health Care peers, as of FY2025
Position among covered Health Care companies that report each metric (minimum 5 peers). A relative position within our covered catalog — not a valuation, quality, or investment judgment. A higher percentile is simply a higher value (for P/E, more expensive on earnings — never "better"). Informational only.
Top 10 scores & list membership
VRTX is not currently in any published Top 10 list. Its scores are below.
Long-term score
Not scored for the long-term list: no shareholder return data.
Short-term score
49.1 #850 of 1,704 scored · #150 of 240 in Health Care
Trend 75th: the price is 7% above the average price paid over the period covered, so the typical buyer over that stretch is showing a gain; volume and participation 70th: it gapped 8.9% above the previous close and has not traded back through the level it left behind — an "unfilled gap", which describes a price range no trade has since crossed and is not a forecast that it will be crossed; weakest is setup 33rd: day-to-day price swings are unusually wide versus its own recent history (wider than about 94% of the past ~6 months). Its score is docked 10 points for overextended (RSI above 75 or stochastic above 90).
Scores as of 21 Aug 2026. Each bar is a percentile: how this company ranked against every company the score ranked, 0–100. A list is a published formula and its output, not a recommendation. Method version 2.
How Vertex Pharmaceuticals looks technically
Vertex Pharmaceuticals (VRTX) is trading 19.2% above its 200-day average, the long-term trend line — a longer-term uptrend. Its 50-day average crossed above its 200-day average about 40 trading days ago — a "golden cross", a bullish long-term signal. A strong uptrend is in place — ADX, a 0–100 trend-strength gauge, is 31, with buyers in control. Momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 67, neither overbought (above 70) nor oversold (below 30). It made a new 20-day high about 3 trading days ago. It is 1.3% below its all-time high.
Trend
8
| Distance from the 200-day | it is trading 19.2% above its 200-day average, the long-term trend line — a longer-term uptrend | +19.2% |
|---|---|---|
| 50-day moving average | its average price over the last 50 trading days — a short-term trend line — is $490.71 | $490.71 |
| 200-day moving average | its average price over the last 200 trading days — the long-term trend line — is $459.67 | $459.67 |
| Swing structure | each recent peak has been higher than the one before it and each dip has been shallower — the pattern chart-watchers call an uptrend, which describes where price has already been and not where it goes next | higher highs and higher lows |
| Last swing turn | its last significant turn was a swing high 11 calendar days ago — the swings before that are what the structure reading is measured on | 11 sessions |
| Wave structure | its recent swings can be read as a five-part upward sequence — what Elliott-wave chartists call an impulse — now in the fourth leg, a pullback against that upward direction; the labelling fails if price closes below 493.61. It is the only labelling that fits, though not with textbook proportions, and it describes the swings already printed, not what comes next. | possible upward five-wave sequence, in wave 4 (atypical proportions) |
| Since the 50/200 cross | its 50-day average crossed above its 200-day average about 40 trading days ago — a "golden cross", a bullish long-term signal | 40 sessions |
| Trend strength (14-day ADX) | a strong uptrend is in place — ADX, a 0–100 trend-strength gauge, is 31, with buyers in control | 30.5 |
Momentum
3
| 14-day RSI | momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 67, neither overbought (above 70) nor oversold (below 30) | 67.1 |
|---|---|---|
| Position in its 14-day range | it is trading near the top of its 14-day range ($465.51 to $555.32) — its "stochastic" reading is 92 out of 100, where 0 would mean closing exactly at the 14-session low and 100 exactly at the high. This measures WHERE the price sits inside its recent range, which is a different question from the RSI beside it: RSI is a momentum gauge, measuring how FAST the price has been moving, so a stock can drift quietly to the bottom of its range with an ordinary RSI, or fall sharply and still sit in the middle. It has been climbing within that range over the last few sessions. | 91.9 |
| Since the MACD crossed zero | MACD, a trend-momentum gauge, is in positive territory (momentum leaning bullish) | 11 sessions |
Range
12
| 52-week high | its highest closing price over the past year (about 252 trading days) was $555.32 | $555.32 |
|---|---|---|
| From the 52-week high | it is 1.3% below its 52-week high (its highest price of the past year) | -1.3% |
| Above the 52-week low | it is 46.5% above its 52-week low (its lowest price of the past year) | +46.5% |
| Below the 52-week high | it is 1.3% below its highest point of the past year | 1.3% |
| Since a 20-day breakout | it made a new 20-day high about 3 trading days ago | 3 sessions |
| Since a 55-day breakout | it made a new 55-day high about 3 trading days ago | 3 sessions |
| All-time high | its highest closing price on record is $555.32 (set on 2026-08-21) | $555.32 |
| Given back of the 52-week move | over the past year its closes ranged ($376.62 to $552.06), and it has given back only a small part of its rise from last year’s low — 2% of it. Chart-watchers call 61.8%-65% given back the "golden pocket" — for this company that is $438.02 to $443.64. It is watched widely enough that orders cluster there, which is the honest reason it matters; it is not a forecast. | 2.3% |
| From the all-time high | it is 1.3% below its all-time high | -1.3% |
| Nearest price level | it is trading 5.2% above a support level at $519.78 — a price it turned at twice since 2024-11-08, most recently on 2025-03-14. Since 2024-08-21 it has 10 such levels below the current price and 0 above. Levels like these describe where the price has reversed or paused before; they are not a forecast of where it will go. | -5.2% |
| All-time low | its lowest closing price on record is $7.25 (set on 1998-08-31) | $7.25 |
| Above the all-time low | it is 7459.3% above its all-time low | +7,459% |
Volatility
5
| Band width vs its own 6 months | day-to-day price swings are unusually wide versus its own recent history (wider than about 94% of the past ~6 months) | 94th percentile |
|---|---|---|
| Typical daily range | in a typical session it travels about $15.96 between its high and its low — about 2.9% of its price. That is its "average true range" over the last 14 sessions, which also counts the distance from the previous close, so a day that opens well away from yesterday counts as the large move it was | $15.96 |
| Bollinger bands (20-day, ±2σ) | most of its recent trading has stayed between about $454.67 and $556.47 — the "Bollinger bands", a range drawn two standard deviations either side of its 20-day average price, which widens when the stock gets more volatile and narrows when it settles | $454.67 – $505.57 – $556.47 |
| Typical daily range (% of price) | its price moves about 2.9% in a typical session — calmer than most companies we cover. This is the average gap between a session's high and low over the last 14 sessions, counting overnight moves, expressed against the current price so it can be compared with companies trading at any price | 2.9% |
| Stretch from the 200-day average | it is trading 5.5 daily ranges above its 200-day average price (19.2% above it in plain percentage terms) — a way of asking how far it has stretched from its own average in units of how far it normally moves in a day, so a calm company and a jumpy one can be compared on the same scale | 5.5 daily ranges above its 200-day average |
Volume
1
| Volume vs its 30-day average | trading volume is about normal versus its 30-day average | 0.82× |
|---|
Analyst
2
| Change in the average price target | analysts have raised their average price target by 0.7% since the prior reading | +0.7% |
|---|---|---|
| Change in the consensus rating | the analyst consensus rating is unchanged since the prior reading | unchanged |
Candlestick patterns
1
| Since a bullish engulfing | 4 sessions ago it opened below the previous session's close and finished above that session's open — a "bullish engulfing" pair, where one up day more than undid the down day before it | 4 sessions ago |
|---|
Price gaps
2
| Gap at the open | it opened on 2026-08-21 0.9% above the previous session's close — an overnight gap, the part of the move that happened while the market was shut, and had not traded back through that level by the close | +0.9% |
|---|---|---|
| Open gap | it gapped 8.9% above the previous close 9 sessions ago and has not traded back through the level it left behind at 496.07 — an "unfilled gap", which describes a price range no trade has since crossed and is not a forecast that it will be crossed | +8.8% |
Price streaks
1
| Closing streak | it closed higher in its latest session, after a session that did not close higher — a single up day rather than a run | 1 session up |
|---|
Relative strength
4
| vs market, 1 month | over the past 1 month this stock beat the market by 11.4 percentage points (the stock gained 13.7% while the market gained 2.3%) | +11.4% |
|---|---|---|
| vs market, 3 months | over the past 3 months this stock beat the market by 23.3 percentage points (the stock gained 26.4% while the market gained 3.1%) | +23.3% |
| vs market, 6 months | over the past 6 months this stock beat the market by 3.9 percentage points (the stock gained 14.9% while the market gained 11.1%) | +3.9% |
| vs market, 12 months | over the past 12 months this stock beat the market by 17.4 percentage points (the stock gained 37.9% while the market gained 20.5%) | +17.4% |
Signal agreement
2
| Bullish technical signals | 7 of the 9 technical signals we can compute for it are currently in a bullish state: a strong uptrend, with buyers in control, a "golden cross" — its 50-day average is above its 200-day, trading above its 200-day average, a fresh 20-day high, MACD momentum is positive, outperforming the market over 6 months, trading above the Ichimoku cloud — these describe past price behaviour, not a forecast | 7 of 9 |
|---|---|---|
| Bearish technical signals | 1 of the 9 technical signals we can compute for it is currently in a bearish state: near the top of its 14-day range (overbought) — these describe past price behaviour, not a forecast | 1 of 9 |
Trend (Ichimoku cloud)
1
| Vs the Ichimoku cloud | trading 11% above the Ichimoku cloud — a band drawn from where its own highs and lows sat up to 2026-07-16 and projected forward over today's price, the side traders read as an established uptrend, with the band below acting as the level that would have to give way. The band itself is moderate, spanning 3.6% of the share price. | +11.5% |
|---|
Volume-weighted price
2
| Vs this year’s average price paid | the price is 17% above the average price paid so far this year, so the typical buyer over that stretch is showing a gain. That average is $467.88 — a volume-weighted average of daily closes over 157 sessions, not a true tick-by-tick VWAP. | +17.1% |
|---|---|---|
| Vs the average paid since it last reported | the price is 7% above the average price paid since it last reported on 2026-08-03 (its 8-K), so the typical buyer over that stretch is showing a gain. That average is $512.24 — a volume-weighted average of daily closes over 15 sessions, not a true tick-by-tick VWAP. | +7.0% |
Price levels it has turned at before
VRTX last closed at $548.05 on 2026-08-21. Since 2024-08-21 it has turned at 10 prices below its last close and 0 above; the 3 nearest below are listed, nearest first.
| Level | Side | Distance | Evidence |
|---|---|---|---|
| $519.78 | Support | 5.2% below the last close | turned there twice · 2024-11-08 to 2025-03-14 |
| $501.90 | Support | 8.4% below the last close | turned there six times · 2024-08-30 to 2026-03-10 |
| $487.52 | Support | 11.0% below the last close | turned there 7 times · 2024-09-16 to 2026-07-28 |
A level is a price this company reversed or paused at more than once — they describe past behaviour, not a forecast of where the price will go.
Wave structure
Its recent swings can be read as a five-part upward sequence — what Elliott-wave chartists call an impulse — now in leg 4 of five, a pullback against that direction.
This labelling fails — stops being a possible reading at all — if it closes below $493.61.
It is the only labelling that fits these swings, though its proportions are not the textbook ones.
On past moves of this shape the leg has usually ended somewhere between $505.84 and $527.13 — that is where it has tended to end if the count holds, not a forecast of where the price goes.
This reading has stood for 5 trading days, since 2026-08-17.
Read from daily closes as of 2026-08-21.
An Elliott-wave count describes the swings already printed and the level that would disprove it. It is not a forecast, a target, or advice.
Screens: Trading above the 200-day moving average · Near the 52-week high · Broke out to a new 20-day high · in a strong, established uptrend (ADX) · Near the all-time high · At the top of its 14-day range (stochastic above 80) | Learn: moving average · golden cross · adx · rsi · breakout · all time high
Based on daily closing prices as of 2026-08-21. Describes past price behavior only — informational, not financial advice.
Analyst consensus
- Consensus ratingBuy (1.62 mean, 1=Strong Buy…5=Strong Sell) — 25 analysts
- Mean price target$563.12 range $350.00 – $672.00; median $570.00
Analyst estimates, as of 2026-08-18. These are third-party analyst opinions and price targets, aggregated — not a recommendation, prediction, or advice from stocks-llm. Informational only.
Analyst EPS estimate for VRTX
- Consensus EPS estimate$4.91 next reporting period, as of 2026-08-18
Change over time is not available yet: it needs two readings of the same reporting period at least 30 days apart, and we have been recording these estimates since 2026-08-04. An estimate for a DIFFERENT quarter is not a revision, so a reading from before the last report is never compared with one after it.
The consensus estimate for the next reporting period, and how it has moved between readings of that SAME period. A change is measured only between readings estimating one period — when a company reports, the consensus moves to the next quarter and the two numbers are not comparable. Informational only, not a forecast and not advice.
Key risks (from latest filing)
["High concentration of revenue from cystic fibrosis medicines; potential for future competition or reimbursement challenges.","Complexity and high manufacturing/administration costs associated with gene therapies like CASGEVY.","Inherent uncertainty in clinical trial outcomes and the regulatory approval process for new drug candidates."]
What changed in the latest 10-Q
AI-assisted comparison of VRTX's 10-Q filed 2026-05-05 against the prior one filed 2025-11-04.
Management's Discussion & Analysis (MD&A)
- Added:
- Newer filing (2026-05-05) adds: 'We are also preparing for the anticipated launch of povetacicept, a potential treatment for IgA nephropathy ("IgAN")' in the Overview section
- Newer filing adds specific financial metrics: Q1 2026 total revenues of $3.0 billion vs Q1 2025 of $2.8 billion
- Newer filing adds: 'Cost of sales as a percentage of net product revenues was 13.2% in each of the first quarters of 2026 and 2025'
- Newer filing adds: Total cash increased to $13.0 billion as of March 31, 2026 vs $12.3 billion as of December 31, 2025
- Newer filing adds ALYFTREK and TRIKAFTA label extensions expanding availability to approximately 95% of all people with CF in the U.S., with approximately 800 newly eligible people
- Newer filing adds: ALYFTREK reimbursement agreements in Scotland, Spain, Sweden, Switzerland, New Zealand, Israel, and Finland
- Newer filing adds: Q1 2026 CASGEVY product revenues of $43 million
- Newer filing adds: CASGEVY pricing agreement for Germany with details on accelerated pediatric review
- Newer filing adds: More than 1 million prescriptions filled for JOURNAVX since March 2025 launch, with over 350,000 in Q1 2026 and $29 million in revenues
- Newer filing adds: JOURNAVX Medicare Part D coverage agreement effective May 1 covering approximately 10 million lives
- Newer filing adds: Approximately 240 million individuals have reimbursed access to JOURNAVX across payers
- Newer filing adds: ALYFTREK clinical trial positive results in children 2-5 years with expected global submissions in first half of 2026
- Newer filing adds: TRIKAFTA clinical trial positive results in children 1 to less than 2 years with begun submissions for approvals
- Newer filing adds: Povetacicept rolling BLA submission to FDA completed in March 2026 with Priority Review Voucher
- Newer filing adds: Phase 2/3 OLYMPUS trial for povetacicept in pMN with Phase 3 portion initiated
- Newer filing adds: AMPLITUDE Phase 2/3 trial interim analysis cohort enrollment completed with data expected in early 2027
- Newer filing adds: Zimislecel internal manufacturing analysis completed and dosing resumed in Phase 1/2/3 trial
- Removed:
- Older filing (2025-11-04) stated 'Our clinical-stage pipeline includes programs in CF, SCD, beta thalassemia, neuropathic pain, type 1 diabetes, IgA nephropathy, primary membranous nephropathy and other autoimmune renal diseases and cytopenias' - newer version changes 'autoimmune renal diseases' to 'autoimmune diseases'
- Older filing contained December 2024 FDA approval details for ALYFTREK and overview section describing CASGEVY and JOURNAVX approvals - newer filing relocates these to Business Updates section
- Older filing reported Q3 2025 net product revenues of $3.1 billion vs Q3 2024 of $2.8 billion - replaced with Q1 2026 and Q1 2025 data
- Older filing reported cash of $12.0 billion as of September 30, 2025 - replaced with $13.0 billion as of March 31, 2026
- Older filing stated cost of sales was 13.5% and 14.2% in Q3 2025 and Q3 2024 - newer states 13.2% for both Q1 periods
- Older filing described TRIKAFTA trial in children 12-24 months completed in October with expected submissions in first half of 2026 - newer describes positive results and begun submissions
- Older filing stated ALYFTREK enrollment completed in 2-5 year trial with data expected first half of 2026 - newer describes positive results with submissions expected first half of 2026
- Older filing described CASGEVY Phase 3 trials in 5-11 year olds with expected dosing completion in Q4 2025 - newer describes pediatric submission completed with FDA Commissioner's National Priority Voucher
- Older filing stated approximately 300,000 JOURNAVX prescriptions filled through mid-October 2025 with over 170 million covered lives - newer reports over 1 million total prescriptions with 240 million covered lives
- Older filing described zimislecel enrollment completion in Phase 1/2/3 trial and temporary postponement - newer states manufacturing analysis completion and dosing resumption
- Reworded:
- Overview description changed from 'other autoimmune renal diseases and cytopenias' to 'other autoimmune diseases and cytopenias' in newer filing
- Business Updates structure reorganized - newer filing integrates regulatory approvals into business updates rather than overview paragraph
- Reporting period changed from Q3 2025 (older) to Q1 2026 (newer) affecting all comparative financial metrics
- Language shift from 'anticipated progress' narrative to 'completed/achieved' language for several pipeline programs in newer filing
- Notes:
- The two filings compare different quarters (Q3 2025 in older filing vs Q1 2026 in newer filing), making direct financial comparisons reflect both period differences and actual changes
- Text appears truncated at end of both versions, particularly regarding zimislecel details
- Some product updates reflect progression of clinical trials from enrollment phase (older) to data/submission phase (newer)
Risk Factors
The two filings could not be meaningfully compared for this section.
AI-assisted comparison of two SEC filing sections. It describes wording and theme changes only, makes no materiality, legal, or investment judgement, and is not financial advice. Informational only — not financial advice.
Insider activity (SEC Form 4)
0 open-market purchases and 9 open-market sales by insiders in the last 90 days.
- Last 90 days0 buys · 9 sells ($7M) — 4 selling insiders
- Last 180 days0 buys · 15 sells ($11M) — 6 selling insiders
Activity heuristic: net selling (a transparent product heuristic from the counts above, not a prediction or advice)
Most recent open-market transaction: 2026-07-02. As of 2026-08-24.
View full insider trading history → View SEC Form 3/4/5 filingsAsk about VRTX's insider activity →
Only open-market purchases (SEC code P) and sales (code S) are counted here. Option exercises, vesting/awards, gifts, and shares withheld for taxes are excluded — they are compensation or mechanical, not open-market conviction. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan) and are not necessarily bearish; open-market buying is not a recommendation to buy. Informational only — not financial advice.
Congressional trading disclosures
U.S. House members publicly disclose their own, their spouse's, and dependent children's stock transactions under the STOCK Act. We hold 11 matched disclosures for VRTX from U.S. House Clerk Periodic Transaction Report filings.
Congressional trading disclosures →Institutional ownership (13F)
6 institutional 13F filers reported holding VRTX as of 2026-03-31 (quarter-end position, filed within 45 days).
- Distinct 13F filers 6
- Reported shares held 38,786,464
- Reported value $17,319,707,317
reported quarterly holdings change (2025-12-31 → 2026-03-31): 0 new, 2 increased, 4 decreased, 1 exited. Change counts cover only managers that filed 13F reports in BOTH quarters, derived between two quarter-end snapshots — not same-day trades; a single manager is never said to have "bought" or "sold".
Institutional holdings are quarter-end long positions reported on SEC Form 13F-HR, filed up to 45 days after the quarter ends — they are delayed, are not real-time trades, exclude short positions and most non-US securities, and are not investment advice. Any increase/decrease is a reported change between two quarterly snapshots, not a same-day purchase or sale. These are quarter-end snapshots from the 13F filings on SEC EDGAR, filed within 45 days — not real-time, and any change is a difference between two quarterly reports, not a same-day trade. Informational only — not financial advice.
Short interest (FINRA)
VRTX had 3,942,936 shares of reported short interest as of the 2026-07-31 FINRA settlement date (delayed, bi-monthly; not real-time).
VRTX had 1.56% of its shares outstanding sold short as of the 2026-07-31 FINRA settlement date (percent of FLOAT would be higher — float is not disclosed in the source). FINRA reported 2.99 days to cover at the same settlement.
- Reported short interest (shares) 3,942,936
- Short interest (% of shares outstanding) 1.56%
- Prior settlement (shares) 4,986,691
- Reported change -20.93%
- Days to cover (reported) 2.99
Reported to FINRA as of the 2026-07-31 settlement date. Short interest is reported to FINRA and published on a delayed, bi-monthly schedule (as of a settlement date, disseminated roughly eight business days later) — it is NOT real-time, does not cover every venue or all US trading, and is not a short-squeeze prediction or investment advice. Days-to-cover is the value FINRA reports; percent of float is not shown because the source file carries no share-count denominator — where a percent appears it is of shares OUTSTANDING, the larger base, and is therefore a floor on percent of float. Informational only — not financial advice.
Competitors & peers
- AbbVie (ABBV)
- Amgen (AMGN)
- Gilead Sciences (GILD)
- Regeneron Pharmaceuticals (REGN)
- Bluebird Bio (BLUE)
- CRISPR Therapeutics (CRSP)
AI-enriched competitor set. Linked names are companies covered by stocks-llm; other named peers are shown for reference only.
Compare VRTX vs…
Vertex Pharmaceuticals is found in…
VRTX shows up in…
Frequently asked questions
What does Vertex Pharmaceuticals (VRTX) do?
Vertex Pharmaceuticals is a global biotechnology company focused on developing and commercializing transformative medicines for serious diseases. The company is primarily known for its portfolio of cystic fibrosis (CF) treatments and has expanded into gene therapies for sickle cell disease and beta thalassemia, as well as development programs for acute and neuropathic pain.
What sector is Vertex Pharmaceuticals (VRTX) in?
Vertex Pharmaceuticals (VRTX) is classified in the Health Care sector. Its industry is Biotechnology. It trades on NASDAQ.
Who are Vertex Pharmaceuticals's (VRTX) competitors?
Notable peers of Vertex Pharmaceuticals (VRTX) include AbbVie, Amgen, Gilead Sciences, Regeneron Pharmaceuticals and Bluebird Bio. This peer set is informational only — not financial advice.
Has there been recent Congressional stock trading in VRTX?
Yes — we hold 11 matched STOCK Act disclosures for VRTX from U.S. House Clerk Periodic Transaction Report filings. These are legally-required disclosures (often filed 30–45 days after the trade), may belong to a U.S. House member, their spouse, or a dependent child, and are not an indicator of company performance or investment advice.
Is Vertex Pharmaceuticals (VRTX) overbought or oversold right now?
Vertex Pharmaceuticals (VRTX) is currently neither overbought nor oversold — its 14-day RSI (a 0–100 momentum gauge) is 67, in the neutral middle (as of 2026-08-21). RSI describes recent price momentum, not a forecast — informational only, not financial advice.
Where does stocks-llm's data on VRTX come from?
Fundamentals and prices come from market data, as of 2026-08-24; company filings and profile facts come from SEC EDGAR. All figures are delayed daily-close data shown with their as-of date — informational only, not financial advice.
Fundamentals: market data, as of 2026-08-24. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-08-21.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date.